Liminatus Pharma (LIMN) vs Scilex (SCLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Scilex is the larger company by market cap ($4.0 million vs $3.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LIMN | SCLX |
|---|---|---|
| Share price | $2.51 | $0.5658 |
| Market cap | $3.37M | $3.98M |
| 1-day change | -10.68% | -12.95% |
| YTD return | — | -92.55% |
| 1-year return | — | -95.96% |
| 5-year return | — | -99.74% |
| Forward P/E | — | 0.78 |
| EPS (TTM) | $-23.50 | $-49.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $30.25M |
| Revenue growth (YoY) | — | -46.54% |
| Net income (latest FY) | $-10.21M | $-374.05M |
| Gross margin | — | 415.83% |
| Operating margin | — | -1143.71% |
| Net margin | — | -1236.42% |
| 52-week high | $141.50 | $14.34 |
| 52-week low | $2.40 | $0.50 |
| Distance from 52-week high | -98.23% | -96.05% |
| Average volume | 30.88K | 56.11K |
| Shares outstanding | 1.34M | 7.03M |
| Employees | 1 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1 employees
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
LIMN vs SCLX FAQ
Which is bigger, Liminatus Pharma or Scilex?
Scilex (SCLX) is larger, with a market capitalization of $3.98M compared with $3.37M for Liminatus Pharma (LIMN).
Are Liminatus Pharma and Scilex in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.